LeMaitre Vascular (LeMaitre Vascular) Long-Term Capital Lease Obligation

: $16.6 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

LeMaitre Vascular's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $16.6 Mil.

LeMaitre Vascular's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($14.4 Mil) to Sep. 2023 ($14.1 Mil) but then increased from Sep. 2023 ($14.1 Mil) to Dec. 2023 ($16.6 Mil).

LeMaitre Vascular's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($14.1 Mil) to Dec. 2022 ($14.7 Mil) and increased from Dec. 2022 ($14.7 Mil) to Dec. 2023 ($16.6 Mil).

LeMaitre Vascular Long-Term Capital Lease Obligation Historical Data

The historical data trend for LeMaitre Vascular's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LeMaitre Vascular Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

13.96

14.79

14.07

14.71

16.62

LeMaitre Vascular Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation																14.71	14.45	14.45	14.13	16.62

LeMaitre Vascular (NAS:LMAT) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

LeMaitre Vascular Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of LeMaitre Vascular's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

LeMaitre Vascular (LeMaitre Vascular) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LeMaitre Vascular Inc (NAS:LMAT) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

LHU:Germany

Address

63 Second Avenue, Burlington, MA, USA, 01803

Website

https://www.lemaitre.com

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Executives

George W Lemaitre	director, 10 percent owner, officer: Chairman, President and CEO	342 BUNKER HILL STREET, #2B, CHARLESTOWN MA 02129
Bridget A Ross	director	C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
John A Roush	director	C/O GSI GROUP INC., 125 MIDDLESEX TURNPIKE, BEDFORD MA 01730-1409
Lawrence J Jasinski	director	SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760
David B Roberts	director, officer: CFO and Director	55 BRADFORD STREET, NEEDHAM MA 02492
Trent G Kamke	officer: Senior V. P., Operations	61 WILLOWDEAN AVENUE, WEST ROXBURY MA 02132
Martha Shadan	director	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Pellegrino Joseph P Jr	officer: Executive V.P. Finance	68 BEACON STREET, BOSTON MA 02108
Michael H Thomas	director	P.O. BOX 2207, NOKOMIS FL 34274-2207
Peter R Gebauer	officer: President, International OP	AM WALDFELD 17, BAD SODEN 2M 65812
Michael T Wijas	officer: VP of Sales, The Americas	C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON MA 01803
Lemaitre Cornelia W	director, officer: V.P., Human Resources,Director	8 SUNSET ROCK ROAD, ANDOVER MA 01810
Russell D Hays	director	C/O BIOSOURCE INTERNATIONAL INC, 542 FLYNN RD, CAMARILLO CA 93012
Robert V Linden	officer: VP, North American Sales	236 WOODEN BRIDGE ROAD, HOLLAND PA 18966
Thorndike William N Jr	director	HOUSATONIC PARTNERS, 800 BOYLSTON STREET, SUITE 2220, BOSTON MA 02199